To combine peripheral blood indices and clinical factors in a prognostic score for metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 dichloride ([223Ra]RaCl2).
The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study) / Bauckneht, Matteo; Rebuzzi, Sara Elena; Signori, Alessio; Frantellizzi, Viviana; Murianni, Veronica; Lodi Rizzini, Elisa; Mascia, Manlio; Lavelli, Valentina; Donegani, Maria Isabella; Ponzano, Marta; Gaudiano, Angela; Stazza, Maria Lina; Licari, Maria; Cavallini, Letizia; Laghi, Viola; Cindolo, Luca; Maggi, Martina; Sciarra, Alessandro; Mammucci, Paolo; Sambuceti, Gianmario; Costa, Renato Patrizio; Spanu, Angela; Rubini, Giuseppe; Monari, Fabio; De Vincentis, Giuseppe; Fornarini, Giuseppe. - In: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. - ISSN 1619-7070. - (2022). [10.1007/s00259-021-05550-6]
The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study)
Stazza, Maria Lina;Spanu, Angela;
2022-01-01
Abstract
To combine peripheral blood indices and clinical factors in a prognostic score for metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 dichloride ([223Ra]RaCl2).| File | Dimensione | Formato | |
|---|---|---|---|
|
Bauckneht2021_Article_ThePrognosticPowerOfInflammato.pdf
accesso aperto
Tipologia:
Versione editoriale (versione finale pubblicata)
Licenza:
Creative commons
Dimensione
1.44 MB
Formato
Adobe PDF
|
1.44 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
